王振强, 耿涛, 吕树泉, 冯玲, 张庆江, 苏秀海, 王庆海, 张淑芳, 陈晶晶. “分消走泄法”对高尿酸血症合并代谢综合征患者的疗效[J]. 实用临床医药杂志, 2022, 26(16): 36-41. DOI: 10.7619/jcmp.20220956
引用本文: 王振强, 耿涛, 吕树泉, 冯玲, 张庆江, 苏秀海, 王庆海, 张淑芳, 陈晶晶. “分消走泄法”对高尿酸血症合并代谢综合征患者的疗效[J]. 实用临床医药杂志, 2022, 26(16): 36-41. DOI: 10.7619/jcmp.20220956
WANG Zhenqiang, GENG Tao, LYU Shuquan, FENG Ling, ZHANG Qingjiang, SU Xiuhai, WANG Qinghai, ZHANG Shufang, CEHN Jingjing. Therapeutic effect of "Fenxiao Zoxie Method"in patients with metabolic syndrome complicated with hyperuricemia[J]. Journal of Clinical Medicine in Practice, 2022, 26(16): 36-41. DOI: 10.7619/jcmp.20220956
Citation: WANG Zhenqiang, GENG Tao, LYU Shuquan, FENG Ling, ZHANG Qingjiang, SU Xiuhai, WANG Qinghai, ZHANG Shufang, CEHN Jingjing. Therapeutic effect of "Fenxiao Zoxie Method"in patients with metabolic syndrome complicated with hyperuricemia[J]. Journal of Clinical Medicine in Practice, 2022, 26(16): 36-41. DOI: 10.7619/jcmp.20220956

“分消走泄法”对高尿酸血症合并代谢综合征患者的疗效

Therapeutic effect of "Fenxiao Zoxie Method"in patients with metabolic syndrome complicated with hyperuricemia

  • 摘要:
    目的 观察“分消走泄法”对高尿酸血症合并代谢综合征的疗效。
    方法 选择代谢综合征治疗患者200例, 随机分为观察组和对照组,每组100例。对照组给予常规运动及饮食干预,给予常规治疗高血压、糖尿病、高血脂的药物,口服盐酸吡格列酮胶囊30 mg, 1次/d, 共治疗60 d。观察组在对照组基础上增用祛湿降浊方。比较2组患者治疗前后相关指标、临床疗效、血尿酸水平、生活质量。
    结果 治疗前, 2组空腹血糖(FBG)、餐后2 h血糖(2 hPBG)、糖化血红蛋白(HbA1c)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、血清总胆固醇(TC)、收缩压(DBP)、舒张压(SBP)、体质量、腰围、体质量指数(BMI)比较,差异无统计学意义(P>0.05); 治疗后60 d,观察组HDL-C高于对照组,其余其余代谢综合征相关指标均低于对照组,差异有统计学意义(P < 0.05)。2组患者治疗60 d后各项代谢综合征相关指标与治疗前比较均改善,差异有统计学意义(P < 0.05)。观察组总有效率为98.00%, 高于对照组的91.00%, 差异有统计学意义(P < 0.05)。治疗后, 2组UA水平与治疗前比较降低,且观察组UA水平低于对照组,差异有统计学意义(P < 0.05)。2组治疗后世界卫生组织生存质量测定量表(WHOQOL-100)评分高于治疗前,且观察组评分高于对照组,差异有统计学意义(P < 0.05)。
    结论 以“分消走泄法”为理论基础的祛湿降浊方对高尿酸血症合并代谢综合征有良好的临床疗效,能够显著提高治疗有效率,改善患者生存质量,为高尿酸血症合并代谢综合征的治疗提供新的可靠途径。

     

    Abstract:
    Objective To observe the effect of "Fenxiao Zoxie Method" for hyperuricemia complicated with metabolic syndrome.
    Methods A total of 200 patients with metabolic syndrome were selected, and were randomly divided into observation group (n=100) and control group (n=100). Patients in the control group were given routine exercise and diet intervention, routine treatment of hypertension, diabetes, hyperlipidemia drugs, and were orally taken Pioglitazone Hydrochloride Capsules at a dose of 30 mg, one time a day for 60 d. In the observation group, Qushi Jiangzhuo Recipe was added on the basis of the treatment scheme of the control group. The relatedindexes, clinical efficacy, blood uric acid level and quality of life of two groups were compared before and after treatment.
    Results There were no significant differences in fasting blood glucose (FBG), 2 h postprandial blood glucose (2 hPBG), glycosylated hemoglobin (HbA1c), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), serum total cholesterol (TC), systolic blood pressure (DBP), diastolic blood pressure (SBP), body weight, waist circumference and body mass index(BMI) between the two groups (P>0.05). At 60 days after treatment, HDL-C in the observation group was higher than that in the control group, and other metabolic syndrome-related indexes were lower than those in the control group (P < 0.05). After 60 days of treatment, the metabolic syndrome related indexes of the two groups were improved compared with those before treatment, and the differences were statistically significant (P < 0.05). The total effective rate of the observation group was 98.00%, which was significantly higher than 91.00% of the control group(P < 0.05). After treatment, the UA levels of the two groups were lower than those before treatment, and the UA level of the observation group was lower than that of the control group (P < 0.05). The World Health Organization Quality of Life (WHOQOL-100) scores of the two groups after treatment were higher than that before treatment, and the score was higher in the observation group than that of the control group (P < 0.05).
    Conclusion Qushi Jiangzhuo Recipe based on "Fenxiao Zoxie Method" has good clinical efficacy for patients with hyperuricemia complicated with metabolic syndrome. It improves effective rates and quality of life of patients, and can provide a new and reliable way for the treatment of hyperuricemia complicated with metabolic syndrome.

     

/

返回文章
返回